Certara Inc (CERT) - Total Liabilities
Based on the latest financial reports, Certara Inc (CERT) has total liabilities worth $493.79 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Certara Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Certara Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Certara Inc to evaluate short-term liquidity relative to the company's equity base.
Certara Inc Competitors by Total Liabilities
The table below lists competitors of Certara Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lanzhou Haimo Technologies Co
SHE:300084
|
China | CN¥258.19 Million |
|
NanJing Pharmaceutical Co Ltd
SHG:600713
|
China | CN¥26.09 Billion |
|
Mcmillan Shakespeare Ltd
AU:MMS
|
Australia | AU$1.37 Billion |
|
NCR Voyix Corporation
NYSE:VYX
|
USA | $2.79 Billion |
|
Permian Basin Royalty Trust
NYSE:PBT
|
USA | $6.49 Million |
|
Episil Holding
TWO:3707
|
Taiwan | NT$3.66 Billion |
|
Otokar Otomotiv ve Savunma Sanayi AS
IS:OTKAR
|
Turkey | TL62.44 Billion |
|
Emerald Expositions Events Inc
NYSE:EEX
|
USA | $847.80 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Certara Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Certara Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Certara Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Certara Inc (2018–2025)
The table below shows the annual total liabilities of Certara Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $493.79 Million | -4.39% |
| 2024-12-31 | $516.45 Million | +0.03% |
| 2023-12-31 | $516.30 Million | +4.67% |
| 2022-12-31 | $493.26 Million | +4.98% |
| 2021-12-31 | $469.88 Million | +5.06% |
| 2020-12-31 | $447.27 Million | -17.94% |
| 2019-12-31 | $545.02 Million | -2.45% |
| 2018-12-31 | $558.72 Million | -- |
About Certara Inc
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pha… Read more